Latest News

IND Application Submitted to FDA for SynKIR-310 Trial in R/R B-NHL
IND Application Submitted to FDA for SynKIR-310 Trial in R/R B-NHL

April 3rd 2024

An investigational new drug application for SynKIR-310's phase 1 trial targeting relapsed/refractory B-cell non-Hodgkin lymphomas was submitted to the FDA.

Comparing Results with Loncastuximab in the Clinic and Real-World Settings in DLBCL
Comparing Results with Loncastuximab in the Clinic and Real-World Settings in DLBCL

April 1st 2024

PROSPECT Study of Tirabrutinib in R/R PCNSL Completes Part A Enrollment
PROSPECT Study of Tirabrutinib in R/R PCNSL Completes Part A Enrollment

March 27th 2024

FDA Denies Approval of Odronextamab in DLBCL and Follicular Lymphoma
FDA Denies Approval of Odronextamab in DLBCL and Follicular Lymphoma

March 25th 2024

Fitting Loncastuximab Into the Current Landscape of R/R DLBCL
Fitting Loncastuximab Into the Current Landscape of R/R DLBCL

March 21st 2024

More News